Previous 10 | Next 10 |
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 PR Newswire CAESAREA, Israel , Aug. 7, 2023 /PRNewswire/ ...
Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System PR Newswire Strong interest in ProSense from healthcare providers in Canada strengthens market potential ProSense now approved throughout North America ...
2023-07-17 08:16:34 ET Quoin Pharmaceuticals ( QNRX ) -91% . BYND Cannasoft Enterprises ( BCAN ) -47% . Apellis Pharmaceuticals ( APLS ) -33% . Baosheng Media Group Holdings Limited ( BAOS ) -13% . Ebix ( EBIX ) -11% after clarific...
IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Up...
IceCure Medical to Review Recent Progress at Maxim Group's Virtual Healthcare Conference PR Newswire IceCure CEO, Eyal Shamir , to present and conduct Q&A on Wednesday, June 21 st at 11:00 AM Eastern Time on Track 2 CAESAREA, Israel , ...
2023-06-07 10:01:47 ET Gainers: Avrobio ( AVRO ) +10% . Cardiff Oncology ( CRDF ) +8% . IceCure Medical ( ICCM ) +7% . Humacyte ( HUMA ) +6% . TScan Therapeutics ( TCRX ) +4% . Losers: Vaxart ( VXRT ) -27% . Carism...
IceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country PR Newswire Latest system installation in IceCure's global commercial rollout of ProSense CAESAREA, Israel , May 31, 2023 /PR...
2023-05-22 13:18:10 ET IceCure Medical Ltd (ICCM) Q1 2023 Earnings Conference Call May 22, 2023, 10:00 AM ET Company Participants Todd Kehrli - EVC Group, IR Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - Vice President, Business Development and G...
2023-05-22 08:35:16 ET IceCure Medical press release ( NASDAQ: ICCM ): Q1 Net loss of $0.08 per share or $3.77M Revenue of $0.71M (-5.3% Y/Y). Cash and cash equivalents, including short-term deposits, of approximately $20.46 million, compared to $23.66 million as of De...
IceCure Medical Reports First Quarter 2023 Financial & Operational Results IceCure Medical Reports First Quarter 2023 Financial & Operational Results PR Newswire Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at ...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...